December 15, 2008
Last week, I ran a chart on the track record of Complete Response Letters versus approvals from the FDA, demonstrating that the latter is losing in favor of the former. Since then, the balance of power has changed even further. … Continue reading →
September 22, 2008
NEW YORK, September 22, 2008 – Bristol-Myers Squibb Company (NYSE: BMY) today announced that it is increasing its initial offer for ImClone Systems Incorporated (NASDAQ: IMCL) and intends to commence a tender offer for the currently outstanding shares of common … Continue reading →
August 13, 2008
Genentech’s special committee formed to help the Board of Directors pose a response to the Roche purchase proposal has stated that they feel the offer "substantially undervalues" the company, but left open the door for a new bid. Here is … Continue reading →
August 2, 2008
Ok, this is a few days late, but like I said, I was really busy this week. At any rate, here is the complete reprint of the press release from BMS. Bristol-Myers Squibb Proposes to Acquire ImClone Systems for $60.00 … Continue reading →